🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A) for Aditxt, Inc. It's an official notice and information packet sent to shareholders before an annual meeting. Its purpose is to get shareholders to vote on important company matters. This document outlines what those matters are, provides details on the people involved (like directors and executives), and explains the company's recommendations.

👉 The Big Picture: Shareholders are being asked to vote on electing directors, approving auditors, and, most notably, giving the board permission to execute a reverse stock split. This is a critical meeting for the company's future strategy and stock listing.

🏢 What The Company Does

In simple terms… Aditxt, Inc. is a biotech company focused on immune system monitoring and reprogramming. They are developing technologies to better understand immune responses, which could lead to applications in personalized medicine, such as improving vaccine responses or transplant compatibility.

👉 Why it matters: This context helps you understand that the company is in a research and development phase. Biotech firms often need significant capital and can have volatile stock prices, which sets the stage for one of the key proposals.

🔑 The Meeting Agenda & Key Proposals

The virtual annual meeting is on May 1, 2026. Shareholders will vote on these six items:

Elect 5 Directors: Vote for the board nominees.
Ratify the Auditor: Approve dbbmckennon as the accounting firm for 2026.
"Say-on-Pay" Vote: Advisory vote to approve executive compensation.
"Say-on-Frequency" Vote: Decide how often to hold the "Say-on-Pay" vote (every 1, 2, or 3 years).
The Reverse Stock Split Proposal (⭐️ Most Critical): Authorize the board to combine shares into fewer shares (a reverse split) at any ratio from 1-for-2 up to 1-for-250 within the next year.
Adjournment Authorization: Allow the meeting to be postponed if needed to gather more votes.

👉 Why the reverse split is crucial: Companies often propose reverse splits when their stock price is very low, aiming to increase the per-share price to meet exchange listing requirements (like staying on the Nasdaq). This is a major red flag about the company's current stock price and market perception.

🔄 The Reverse Stock Split: The Details

The board is asking for discretion on the exact ratio, which will be determined later. They have one year to implement it if they choose to.

Range: 1-for-2 (least aggressive) to 1-for-250 (most aggressive).
Goal: Typically to boost the stock price per share. For example, a 1-for-10 split would turn 10 shares worth $1 each into 1 share worth $10.
What it signals: This is often a defensive move to avoid being delisted from an exchange due to a low stock price. It can indicate the company's stock has been performing poorly.

👉 What this means for you: If you own 1,000 shares, after a 1-for-10 split, you'd own 100 shares. Your total investment value stays the same initially, but it's a strong signal the company faces challenges.

👥 Board & Governance

The board proposes 5 nominees for election. Three are considered "independent" under Nasdaq rules.

Amro Albanna (CEO): Co-founder with a background in tech startups.
Dr. Shahrokh Shabahang (Chief Innovation Officer): Co-founder with deep biotech R&D experience.
Brian Brady, Charles Nelson, Sylvia Hermina: Independent directors with backgrounds in finance, capital markets, and corporate governance.

The board has three committees: Audit (chaired by Brian Brady), Compensation (chaired by Charles Nelson), and Nominating/Governance (chaired by Sylvia Hermina).

💼 Executive Compensation

The filing details the pay for top executives. Notably, the company states that management has voluntarily forgone their salaried payroll at times in 2024 and 2025, likely to preserve cash.

2025 Named Executive Officers & Salary:

Amro Albanna, CEO: $500,000
Corinne Pankovcin, Chief M&A Officer: $385,008
Dr. Shahrokh Shabahang, Chief Innovation Officer: $325,000
Thomas Farley, CFO: $395,000

👉 The Takeaway: No bonuses, stock awards, or other compensation are listed in the table for these years. The salaries are also noted as "accrued," hinting at potential cash flow constraints where even executive pay might be deferred.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Specialized Focus: Operates in a high-potential area of biotech (immune system tech).
Experienced Team: Founders and executives have relevant scientific and operational backgrounds in the field.
Structured Governance: Has standard board committees and a code of ethics in place.

⚠️ Risks & Concerns:

Reverse Stock Split Proposal: The clearest warning sign. Indicates stock price is likely very low and the company is at risk of not meeting exchange listing standards.
Cash Conservation: Management forgoing salaries suggests the company is tight on cash, common for pre-revenue biotech firms but a risk nonetheless.
Executive Compensation Table: The lack of any bonuses or equity awards in the reported years is unusual and may indicate a lack of performance-based incentives or capital to grant them.

🧠 The Analogy

The company is like a science project running out of poster board. The science (immune tech) is interesting, and the team (directors/executives) knows the subject. But the presentation board (the stock price) is getting too small and flimsy to hold everything up. Now, they're asking the owners (shareholders) for permission to staple two small boards together into one bigger-looking board (the reverse split) to keep the project from being disqualified from the science fair (the stock exchange).

🧩 Final Takeaway

This proxy statement reveals Aditxt is a biotech navigating significant financial headwinds. The overwhelming focus for shareholders should be the reverse stock split proposal, which is a clear indicator of a low stock price and a potential last-ditch effort to maintain its listing. The details on executive pay and cash conservation further underscore the company's challenging financial position.

Aditxt, Inc. — DEF 14A Filing